PLN-74809
- Generic Name
- PLN-74809
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
PLN-74809 is a small-molecule that dually inhibits both αβ and αβ to treat both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical development of this compound. Phase 2a studies are currently evaluating PLN-74809 safety and efficacy for participants with IPF (NCT04396756)across 10 participating countries, and for participants with PSC (NCT04480840). In addition, the compound is also currently in Phase 2a trials (NCT04565249) for the treatment of COVID-19 related acute respiratory distress syndrome.
- Indication
Through dual inhibition of integrins αβ and αβ, PLN-74809 reduces subsequent activation of TGF-β1, which is actively involved in the growth of fibrotic tissue in lung and bile ducts. Further studies showed that PLN-74809 inhibited collagen gene expression in PSC and IPF patient tissue.
- Associated Conditions
- -
- Associated Therapies
- -
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Pliant Therapeutics, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06097260
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Arizona Pulmonary Specialists, Phoenix, Arizona, United States
🇺🇸Dignity Health-St. Josephs Hospital and Medical Center, Phoenix, Arizona, United States
Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Pliant Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05621252
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Pliant Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04565249
- Locations
- 🇺🇸
Advent Health, Orlando, Florida, United States
🇺🇸National Jewish Health, Denver, Colorado, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Pliant Therapeutics, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT04480840
- Locations
- 🇺🇸
Stanford University School of Medicine, Redwood City, California, United States
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Pliant Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT04396756
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸The Emory Clinic, Atlanta, Georgia, United States
Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Pliant Therapeutics, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT04072315
- Locations
- 🇺🇸
Stanford Medical Center, Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.